Today's Johnson & Johnson (JNJ) update.
Johnson & Johnson announced that its candidate drug Duplex-AD for treating moderate-to-severe atopic dermatitis (AD) failed to meet its preset efficacy goals in a Phase IIb proof-of-concept (PoC) study. In other words, the drug's performance on key efficacy metrics fell short of statistical or clinical expectations. Will this impact JNJ's stock price?
Johnson & Johnson (JNJ) Duplex-AD Drug Fails to Meet Primary Endpoint in Phase IIb Clinical Trial. Can Its Stock Price Continue to Rise?
byu/Other-Maximum-linda instocks
Posted by Other-Maximum-linda
2 Comments
Curious how much revenue people here thought this drug could realistically contribute.
JNJ is a dividend king. They aren’t going anywhere and will remain a leader